On 27 december 2023, the shanghai pioneer holdings ltd. (“shanghai pioneer holdings” or “groups”, stock code: 1345. Hk) subsidiary of chongqing pioneer medicines ltd. (chongqing pioneer) entered into an intellectual property transfer agreement with q3 medical services limited (q3). Accordingly, the chongqing vanguard agreed to buy and q3 medically agreed to sell all the intellectual property rights (patents and know-how) held by q3 medical treatments up to the date of the contract, as well as all the newly developed intellectual property rights (possessed assets) in mainland china within three years of the date of the contract。
According to the agreement, q3 medical treatment will transfer, in an exclusive manner, to chongqing pioneers and their affiliates the right to research, develop, import, use, sell, sell, produce and continue to produce products in connection with the targeted assets in mainland china. Chongqing pioneers and their affiliates plan to establish factories in mainland china to develop, produce and sell products under the above-mentioned intellectual property rights. Q3 medical treatment will provide the necessary services and support for the transfer of technology to factories in mainland china。
In addition, q3 medical treatment has the right to exercise its repurchase interest within a certain time after the entry into force of the agreement. In this case, the q3 medical treatment shall refund the full cost incurred by the chongqing vanguard and bear a percentage of the premium. Chongqing pioneers and their affiliates still have exclusive distribution rights in mainland china for all q3 medical products。
Q3 medical care is designed to treat human cavity diseases through micro-intervention, with products covering both vascular and non-vascular areas. The company has the world's leading biodegradability techniques, with two degradable stairwells (akimid and unity b) being the only marketed pancreas degradable stairwells in the world. Compared to the non-degradable staves, akimid and unity b are exempt from secondary surgery to remove, reduce the incidence of complications and reduce the overall cost of treatment, and clinical applications in the market in the european region are increasing rapidly, showing excellent clinical values。
The shanghai pioneer holdings is the leading provider of comprehensive marketing, extension and channel management services for imported medicines and medical equipment products in china. As an internationalized enterprise with a global vision, the shanghai pioneer holdings have established a stable and mutually beneficial long-term partnership with a number of globally recognized pharmaceutical and medical equipment producers, successfully building a platform for the introduction of products for sustainable development and laying out a marketing network covering the entire chinese market, and long-term efforts have shaped the group's unique brand base。
Looking ahead, the acquisition of all the intellectual property rights of q3 medical care in mainland china and the establishment of factories to develop, produce and sell the above-mentioned innovative medical products will contribute to the future strategic transformation of the group from a mere agent to an enterprise where medical product agents develop together with autonomous r & d, production innovation, increase the competitiveness of group products and contribute to steady business growth. In addition, the accelerated registration and domesticization of innovative products in china has facilitated the early use by chinese patients of the world’s most leading health products, reflecting the social impact of this acquisition。
